In:
Pharmaceutical Patent Analyst, Future Science Ltd, Vol. 10, No. 3 ( 2021-05), p. 111-163
Abstract:
The G-protein-coupled cannabinoid receptor type 2 (CB 2 R) is a key element of the endocannabinoid (EC) system. EC/CB 2 R signaling has significant therapeutic potential in major pathologies affecting humans such as allergies, neurodegenerative disorders, inflammation or ocular diseases. CB 2 R agonism exerts anti-inflammatory and tissue protective effects in preclinical animal models of cardiovascular, gastrointestinal, liver, kidney, lung and neurodegenerative disorders. Existing ligands can be subdivided into endocannabinoids, cannabinoid-like and synthetic CB 2 R ligands that possess various degrees of potency on and selectivity against the cannabinoid receptor type 1. This review is an account of granted CB 2 R ligand patents from 2010 up to the present, which were surveyed using Derwent Innovation ® .
Type of Medium:
Online Resource
ISSN:
2046-8954
,
2046-8962
DOI:
10.4155/ppa-2021-0002
Language:
English
Publisher:
Future Science Ltd
Publication Date:
2021
